Your browser doesn't support javascript.
The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ?
Jans, David A; Wagstaff, Kylie M.
  • Jans DA; Nuclear Signaling Lab., Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Melbourne, Australia. Electronic address: David.Jans@monash.edu.
  • Wagstaff KM; Cancer Targeting and Nuclear Therapeutics Lab., Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Melbourne, Australia. Electronic address: Kylie.Wagstaff@monash.edu.
Biochem Biophys Res Commun ; 538: 163-172, 2021 01 29.
Article in English | MEDLINE | ID: covidwho-1125081
ABSTRACT
FDA approved for parasitic indications, the small molecule ivermectin has been the focus of growing attention in the last 8 years due to its potential as an antiviral. We first identified ivermectin in a high throughput compound library screen as an agent potently able to inhibit recognition of the nuclear localizing Human Immunodeficiency Virus-1 (HIV-1) integrase protein by the host importin (IMP) α/ß1 heterodimer, and recently demonstrated its ability to bind directly to IMPα to cause conformational changes that prevent its function in nuclear import of key viral as well as host proteins. Cell culture experiments have shown robust antiviral action towards a whole range of viruses, including HIV-1, dengue, Zika and West Nile Virus, Venezuelan equine encephalitis virus, Chikungunya, pseudorabies virus, adenovirus, and SARS-CoV-2 (COVID-19). Close to 70 clinical trials are currently in progress worldwide for SARS-CoV-2. Although few of these studies have been completed, the results that are available, as well as those from observational/retrospective studies, indicate clinical benefit. Here we discuss the case for ivermectin as a host-directed broad-spectrum antiviral agent, including for SARS-CoV-2.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Ivermectin / SARS-CoV-2 / COVID-19 Drug Treatment / Antiparasitic Agents Type of study: Observational study / Prognostic study Limits: Humans Language: English Journal: Biochem Biophys Res Commun Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Ivermectin / SARS-CoV-2 / COVID-19 Drug Treatment / Antiparasitic Agents Type of study: Observational study / Prognostic study Limits: Humans Language: English Journal: Biochem Biophys Res Commun Year: 2021 Document Type: Article